Electromagnetic Stimulation In Ophthalmology

MagnoVisionTM is an electromagnetic stimulation / iontophoresis medical therapy device that is used without touching the eyeball (bulbus oculi) via a helmet. It is a new method that can be safely used alone or in combination with other treatment methods in the treatment of some retinal and optic nerve diseases that cannot be effectively treated with current methods

Download Brochure Download Clinical Studies


Magnovision


By simultaneously stimulating the retina, optic nerve and visual pathways electromagnetically, it is efficient in the treatment of dystrophic, neurodegenerative, ischemic and traumatic retinal / optic nerve diseases like

  • RETINITIS PIGMENTOSA
  • TRAUMATIC MACULOPATHY
  • DRY TYPE-AGE-RELATED MACULAR DEGENERATION)
  • ADVANCED DIABETIC RETINOPATHY
  • RETINAL VESSEL OCCLUSION
  • DYSTROPHIC / DEGENERATIVE MACULA DISEASES
  • GLAUCOMA
  • RECALCITRANT CHORINC CENTRAL SEROUS CHORIORETINOPATHY (Chronic CSCR)

MagnovisionTM can also be used in combination with other contemporary methods when the current treatment methods are insufficient.

WITH ELECTROMAGNETIC STIMULATION

  • The level of reparative neurotrophic growth factors in the microenvironment increases
  • Growth factor - thyrosine kinase receptor sensitivity and efficiency increase
  • Capillary blood flow in neural tissue increases and thrombocytes are degranulated
  • Chronic inflammatory cytokines in the microenvironment are suppressed
  • Cleaning of harmful metabolic wastes in neural tissue is accelerated
  • With the iontophoresis effect, the concentration and efficiency of growth factors and drugs are increased in the damaged tissues
  • Axonal regeneration of neurons is accelerated
  • Activities of synaptic connections and ion channels in neural tissue is regulated



BY INCREASING THE EFFICACY OF THE GROWTH FACTOR OR STEM CELL THERAPY, MAGNOVISION MAY SLOW OR STOP THE PROGRESSION OF THE RETINITIS PIGMENTOSA, DEEP RETINAL CAPILLARY ISCHEMIA AND CHRONIC CSCR (1-5)

WORLDWIDE THERE ARE APPROXIMATELY

  • 70 MILLION GLAUCOMA
  • 50 MILLION DIABETIC RETINOPATHY
  • 32 MILLION YEARS OF MACULA DEGENERATION
  • 2 MILLION RETINITIS PIGMENTOSA

patients where these progressive eye diseases can result in blindness. While these progressive neurodegenerative diseases can be treated at varying degrees with contemporary treatment methods, in some stages and cases they may be insufficient. MagnoVisionTM therapy device, used alone or in combination with other treatment methods, can slow or stop blindness in appropriate cases.

This medical device has a helmet (A); that stimulates the retina and the visual pathways without touching the eyeball by generating electromagnetic field and a control unit (B); where the treatment parameters are set by the doctor and secured so that it cannot be changed by the patient. High-frequency repetitive electromagnetic stimulation (high-frequency rEMS) generated by the device is a safe and harmless method because it is far below the specified safety limit (5,6).

Since the diseases mentioned above usually require a long-term treatment, the patient can also use the MagnoVisionTM therapy device at home after the treatment parameters in the control unit are set and secured by the physician. The patient or their relatives should contact the physician and / or technical service at recommended intervals or in case of need.

Contact Info

BİORETİNA BİYOTEKNOLOJİ VE BİYOMEDİKAL SAĞLIK YATIRIMLARI A.Ş.

Address:

BİORETİNA BİYOTEKNOLOJİ VE BİYOMEDİKAL SAĞLIK YATIRIMLARI A.Ş. Bahçelievler Mh. 319 Cd. E Blok No:35E/B49 Gölbaşı/ANKARA